ABROCITINIB TREATMENT IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: KEY EFFICACY AND SAFETY RESULTS FROM PHASE 3 TRIALS JADE MONO-1 AND JADE MONO-2

被引：0

作者：

Simpson, Eric L. ^{[1
]}

Silverberg, Jonathan I. ^{[2
]}

Forman, Seth ^{[3
]}

Wollenberg, Andreas ^{[4
]}

Thyssen, Jacob P. ^{[5
]}

Flohr, Carsten ^{[6
]}

Feeney, Claire ^{[7
]}

Biswas, Pinaki ^{[8
]}

DiBonaventura, Marco ^{[9
]}

Cameron, Michael C. ^{[10
]}

Rojo, Ricardo ^{[11
]}

Valdez, Hernan ^{[12
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA

[2] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA

[3] ForCare Clin Res, Dept Dermatol, Tampa, FL USA

[4] Ludwig Maximilian Univ Munich, Dept Dermatol, Munich, Germany

[5] Univ Copenhagen, Dept Dermatol & Allergy, Herlev & Gentofte Hosp, Hellerup, Denmark

[6] St Johns Inst Dermatol, Unit Populat Based Dermatol Res, London, England

[7] Pfizer Ltd, Global Med Affairs Inflammat & Immunol, Tadworth, Surrey, England

[8] Pfizer Inc, Biostat, New York, NY USA

[9] Pfizer Inc, Patient & Hlth Impact Inflammat & Immunol, New York, NY USA

[10] Pfizer Inc, North Amer Med Affairs Inflammat & Immunol, New York, NY USA

[11] Pfizer Inc, Global Prod Dev Inflammat & Immunol, Groton, CT 06340 USA

[12] Pfizer Inc, Global Prod Dev Inflammat & Immunol, New York, NY USA

来源：

ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

OL10

引用

页码：13 / 14

页数：2

共 50 条

[21] Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND
Paller, Amy S.
Cork, Michael J.
Flohr, Carsten
Bangert, Christine
Weidinger, Stephan
Nesnas, John
Farooqui, Saleem A.
Biswas, Pinaki
Watkins, Melissa
Koppensteiner, Herwig
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[22] Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis The JADE TEEN Randomized Clinical Trial
Eichenfield, Lawrence F.
Flohr, Carsten
Sidbury, Robert
Siegfried, Elaine
Szalai, Zsuzsanna
Galus, Ryszard
Yao, Zhirong
Takahashi, Hidetoshi
Barbarot, Sebastien
Feeney, Claire
Zhang, Fan
DiBonaventura, Marco
Rojo, Ricardo
Valdez, Hernan
Chan, Gary
JAMA DERMATOLOGY, 2021, 157 (10) : 1165 - 1173
[23] Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial
Li, Hang
Cheng, Hao
Lu, Qianjin
Lai, Wei
Tao, Xiaohua
Encinas, Gerardo A.
Vyas, Shefali
Wang, Bo
Luo, Xin
Li, Shiqi
CHINESE MEDICAL JOURNAL, 2024, 137 (16) : 1991 - 1992
[24] Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial
Li Hang
Cheng Hao
Lu Qianjin
Lai Wei
Tao Xiaohua
Encinas Gerardo A
Vyas Shefali
Wang Bo
Luo Xin
Li Shiqi
中华医学杂志英文版, 2024, 137 (16)
[25] Efficacy and safety of abrocitinib in combination with topical therapy in adolescents from China with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE TEEN phase 3 trial
Yao, Zhirong
Xu, Aie
He, Li
Ding, Yangfeng
Hu, Guohong
Vyas, Shefali
Wang, Bo
Luo, Xin
Li, Shiqi
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II23 - II24
[26] Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis
Thyssen, J. P.
Yosipovitch, G.
Paul, C.
Kwatra, S. G.
Chu, C. Y.
DiBonaventura, M.
Feeney, C.
Zhang, F.
Myers, D.
Rojo, R.
Valdez, H.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (03) : 434 - 443
[27] Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
Reich, Kristian
Silverberg, Jonathan I.
Papp, Kim A.
Deleuran, Mette
Katoh, Norito
Strober, Bruce
Beck, Lisa A.
de Bruin-Weller, Marjolein
Werfel, Thomas
Zhang, Fan
Biswas, Pinaki
DiBonaventura, Marco D.
Chan, Gary
Johnson, Susan
Farooqui, Saleem A.
Kerkmann, Urs
Clibborn, Claire
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : 2056 - 2066
[28] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the open-label run-in period of JADE REGIMEN
Lebwohl, M. G.
Worm, M.
Gold, L. F. Stein
Bangert, C.
Schmid-Grendelmeier, P.
Khan, T.
Biswas, Pinaki
DiBonaventura, M.
Chan, G.
Terry, K.
Valdez, H.
Clibborn, C.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E73 - E74
[29] Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial
Li, Hang
Cheng, Hao
Lu, Qianjin
Lai, Wei
Tao, Xiaohua
Encinas, Gerardo A.
Vyas, Shefali
Wang, Bo
Luo, Xin
Li, Shiqi
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[30] Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2
Yosipovitch, Gil
Gooderham, Melinda J.
Staender, Sonja
Fonacier, Luz
Szepietowski, Jacek C.
Deleuran, Mette
Girolomoni, Giampiero
Su, John C.
Bushmakin, Andrew G.
Cappelleri, Joseph C.
Feeney, Claire
Chan, Gary
Thorpe, Andrew J.
Valdez, Hernan
Biswas, Pinaki
Rojo, Ricardo
Dibonaventura, Marco
Myers, Daniela E.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (01) : 127 - 138

← 1 2 3 4 5 →